相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
Katrin Liffers et al.
TARGETED ONCOLOGY (2016)
Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma
Mario Venza et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
The requirement of histone modification by PRDM12 and Kdm4a for the development of pre-placodal ectoderm and neural crest in Xenopus
Shinya Matsukawa et al.
DEVELOPMENTAL BIOLOGY (2015)
Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma
Peter Hersey et al.
FUTURE ONCOLOGY (2015)
The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation
Michel DuPage et al.
IMMUNITY (2015)
Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation
Patricia A. Toniolo et al.
JOURNAL OF IMMUNOLOGY (2015)
Polycomb Repressive Complex 2 Confers BRG1 Dependency on the CIITA Locus
Mohamed Abou El Hassan et al.
JOURNAL OF IMMUNOLOGY (2015)
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas
Jinhua Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy
Altaf A. Dar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma
James S. Wilmott et al.
MODERN PATHOLOGY (2015)
Histone Variant H2AZ2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma
Chiara Vardabasso et al.
MOLECULAR CELL (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
K. Cao et al.
ONCOGENE (2015)
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Daniele Perna et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
Daniel Zingg et al.
NATURE COMMUNICATIONS (2015)
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Annelien Verfaillie et al.
NATURE COMMUNICATIONS (2015)
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth
Anthony M. Barsotti et al.
ONCOTARGET (2015)
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification
Matteo Dugo et al.
ONCOTARGET (2015)
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
Jessamy C. Tiffen et al.
ONCOTARGET (2015)
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
Anja Heinemann et al.
ONCOTARGET (2015)
The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy
Altaf A. Dar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
MITF in melanoma: mechanisms behind its expression and activity
Mariusz L. Hartman et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
EZH2: an emerging role in melanoma biology and strategies for targeted therapy
Jessamy Tiffen et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
Modulation of BRAHMA expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation
Aanchal Mehrotra et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
Patrice E. Herait et al.
CANCER RESEARCH (2014)
Histone variants: emerging players in cancer biology
Chiara Vardabasso et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma
A. Mehrotra et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2014)
Is Mcl-1L the new anti-apoptotic effector of B-RAFV600E in melanoma?
Daniele Bergamaschi
EXPERIMENTAL DERMATOLOGY (2014)
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
D. V. Chan et al.
GENES AND IMMUNITY (2014)
Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP
Isabella Venza et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2014)
Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review)
Giulia Grazia et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Decreased Expression of the Chromatin Remodeler ATRX Associates with Melanoma Progression
Zulekha A. Qadeer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
Stuart J. Gallagher et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Melanoma epigenetics: novel mechanisms, markers, and medicines
Jonathan J. Lee et al.
LABORATORY INVESTIGATION (2014)
FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma
Michele B. Weiss et al.
MOLECULAR CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells
Aaron Arvey et al.
NATURE IMMUNOLOGY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy
Nethia Mohana-Kumaran et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
Stuart J. Gallagher et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Histone H3.3 and its proteolytically processed form drive a cellular senescence programme
Luis F. Duarte et al.
NATURE COMMUNICATIONS (2014)
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
David J. Konieczkowski et al.
CANCER DISCOVERY (2014)
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Francesco Spagnolo et al.
ONCOTARGET (2014)
HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen et al.
ONCOTARGET (2014)
Trichostatin A Suppresses EGFR Expression through Induction of MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells
Chih-Yen Tu et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
Deborah J. L. Wong et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
Dominique N. Lisiero et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells
Katherine Woods et al.
FRONTIERS IN ONCOLOGY (2014)
How anti-PD1 treatments are changing the management of melanoma
Peter Hersey et al.
MELANOMA MANAGEMENT (2014)
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
Alexander Roesch et al.
CANCER CELL (2013)
Anti-apoptotic proteins on guard of melanoma cell survival
Mariusz L. Hartman et al.
CANCER LETTERS (2013)
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Miguel F. Segura et al.
CANCER RESEARCH (2013)
A Focus on PD-L1 in Human Melanoma
Peter Hersey et al.
CLINICAL CANCER RESEARCH (2013)
Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma
Christopher S. McKee et al.
EXPERIMENTAL DERMATOLOGY (2013)
Toxicological and metabolic considerations for histone deacetylase inhibitors
Joanna Fraczek et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Epigenetics of melanoma: implications for immune-based therapies
Elisabetta Fratta et al.
IMMUNOTHERAPY (2013)
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Ethan V. Abel et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Cory M. Johannessen et al.
NATURE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity
David M. Woods et al.
MELANOMA RESEARCH (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Beta-catenin inhibits melanocyte migration but induces melanoma metastasis
S. J. Gallagher et al.
ONCOGENE (2013)
Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
A. S. Little et al.
ONCOGENE (2013)
BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene
Srinivas V. Saladi et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis
Jasper Wouters et al.
PLOS ONE (2013)
Phenformin enhances the therapeutic benefit of BRAFV600E inhibition in melanoma
Ping Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells
M-C Chen et al.
CELL DEATH & DISEASE (2013)
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
F. Lai et al.
CELL DEATH & DISEASE (2013)
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Yan Ye et al.
NATURE COMMUNICATIONS (2013)
Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors
Kevin Cronin et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
Ji Eun Kim et al.
Frontiers in Genetics (2013)
Immunotherapy of cancer in 2012
John M. Kirkwood et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Fei Su et al.
CANCER RESEARCH (2012)
Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors
Ken Saijo et al.
CANCER SCIENCE (2012)
Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma
Christine Guo Lian et al.
CELL (2012)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
The tumor suppressor HINT1 regulates MITF and β-catenin transcriptional activity in melanoma cells
Giannicola Genovese et al.
CELL CYCLE (2012)
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2012)
Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
Changgeng Qian et al.
CLINICAL CANCER RESEARCH (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
K. J. Basile et al.
ONCOGENE (2012)
Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation
Yu-Wen Zhang et al.
PLOS ONE (2012)
A Combination of H2A.Z and H4 Acetylation Recruits Brd2 to Chromatin during Transcriptional Activation
Ryan Draker et al.
PLOS GENETICS (2012)
Mutant BRAF Melanomas-Dependence and Resistance
Poulikos I. Poulikakos et al.
CANCER CELL (2011)
Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
Mahadev Rao et al.
CANCER RESEARCH (2011)
Combinatorial Patterning of Chromatin Regulators Uncovered by Genome-wide Location Analysis in Human Cells
Oren Ram et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Apoptosis and oncogenesis: give and take in the BCL-2 family
Fabien Llambi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
HDAC Inhibitor Vorinostat Enhances the Antitumor Effect of Gefitinib in Squamous Cell Carcinoma of Head and Neck by Modulating ErbB Receptor Expression and Reverting EMT
Francesca Bruzzese et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
Marialuisa Sensi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
Chia-Wei Chou et al.
PLOS ONE (2011)
Critical Analysis of Simultaneous Blockage of Histone Deacetylase and Multiple Receptor Tyrosine Kinase in the Treatment of Prostate Cancer
Steffen Wedel et al.
PROSTATE (2011)
SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells
Jiri Vachtenheim et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
BRG1 expression is increased in human cutaneous melanoma
H. Lin et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity
Cristina Garrido et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
FOXD3 Is a Mutant B-RAF-Regulated Inhibitor of G1-S Progression in Melanoma Cells
Ethan V. Abel et al.
CANCER RESEARCH (2010)
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
Alexander Roesch et al.
CELL (2010)
HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1
Lina Pan et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2010)
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Michael Dickinson et al.
INVESTIGATIONAL NEW DRUGS (2010)
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8
Avnish Kapoor et al.
NATURE (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma
B. Keenen et al.
ONCOGENE (2010)
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
C. C. Jiang et al.
CELL DEATH & DISEASE (2010)
Small molecules and targeted therapies in distant metastatic disease
P. Hersey et al.
ANNALS OF ONCOLOGY (2009)
Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
Peter Hersey et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
Matthew W. VanBrocklin et al.
CANCER RESEARCH (2009)
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
Dan D. Vo et al.
CANCER RESEARCH (2009)
HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
Xiaoping Huang et al.
CANCER RESEARCH (2009)
Loss of SNF5 Expression Correlates with Poor Patient Survival in Melanoma
Hanyang Lin et al.
CLINICAL CANCER RESEARCH (2009)
BRAF Signaling and Targeted Therapies in Melanoma
Nathalie Dhomen et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells
Nathaniel B. Goldstein et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a
Therese M. Becker et al.
MOLECULAR CANCER (2009)
Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis
Karen Boisvert-Adamo et al.
MOLECULAR CANCER RESEARCH (2009)
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
Alejandro Villagra et al.
NATURE IMMUNOLOGY (2009)
Regulation of protein turnover by acetyltransferases and deacetylases
Karin Sadoul et al.
BIOCHIMIE (2008)
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
A. Francesca Setiadi et al.
CANCER RESEARCH (2008)
Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma
Takashi Murakami et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage
Satoru Yokoyama et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival
Robert A. Cartlidge et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?
Jerry E. Chipuk et al.
TRENDS IN CELL BIOLOGY (2008)
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells
A. Nazmul H. Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
An epigenetic vaccine model active in the prevention and treatment of melanoma
A. Nazmul H. Khan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
A role for EZH2 in silencing of IFN-γ inducible MHC2TA transcription in uveal melanoma
Tjadine M. Holling et al.
JOURNAL OF IMMUNOLOGY (2007)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1
Yu Fang Wang et al.
CLINICAL CANCER RESEARCH (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
Trine Lillehammer et al.
JOURNAL OF GENE MEDICINE (2007)
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Liqing Zhuang et al.
MODERN PATHOLOGY (2007)
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells
Alessandra Valentini et al.
CANCER BIOLOGY & THERAPY (2007)
Epigenetic regulation of tumor endothelial cell anergy:: Silencing of intercellular adhesion molecule-1 by histone modifications
Debby M. E. I. Hellebrekers et al.
CANCER RESEARCH (2006)
The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes
Ivana L. de la Serna et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1,-A2,-A3, and-A12 in human cancer cells
Frank Wischnewski et al.
MOLECULAR CANCER RESEARCH (2006)
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
S Ropero et al.
NATURE GENETICS (2006)
Differential expression of selected histone modifier genes in human solid cancers
Hilal Ozdag et al.
BMC GENOMICS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors
MV Blagosklonny et al.
CANCER RESEARCH (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo
L Sanchez-Perez et al.
CANCER RESEARCH (2005)
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells
SC Maggio et al.
CANCER RESEARCH (2004)
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
CY Gui et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells
A Burgess et al.
ONCOGENE (2004)
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors
F Facchetti et al.
APOPTOSIS (2004)
An epigenetically altered tumor cell vaccine
ANH Khan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway
D Bandyopadhyay et al.
CANCER RESEARCH (2004)
The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis
XD Zhang et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Apoptosis and melanoma: molecular mechanisms
MR Hussein et al.
JOURNAL OF PATHOLOGY (2003)
The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines
EI Campos et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines
F Leoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression
BP Ashburner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Duration of nuclear NF-κB action regulated by reversible acetylation
LF Chen et al.
SCIENCE (2001)
Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
TS Weiser et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Histone deacetylases specifically down-regulate p53-dependent gene activation
LJ Juan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL
CL Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
分享论文
